Tag «PHASE 2»

VX 148

It’s only fair to share… VX 148 297730-05-3 Name: VX-148 CAS#: 297730-05-3 Chemical Formula: C23H25N5O4 Exact Mass: 435.19065 Molecular Weight: 435.48 Elemental Analysis: C, 63.44; H, 5.79; N, 16.08; O, 14.70 Molecular Weight 435.48 Formula C23H25N5O4 CAS No. 297730-05-3 (VX 148); Chemical Name Carbamic acid, N-[(1S)-1-[3-[[[(4-cyano-3-methoxyphenyl)amino]carbonyl]amino]phenyl]ethyl]-, (1R)-1-(cyanomethyl)propyl ester MOA:Inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitorIndication:PsoriasisStatus:Phase Ⅱ (Discontinued)Company:Vertex (Originator) …

VX- ? (3-[2-(4-fluorophenyl)-lH-indol-3-yl]-N-[(3S,4R)-4-hydroxy-2- oxo-pyrrolidin-3-yl ] propanamide)

It’s only fair to share… VX- ? CAS  2446817-72-5 HYDRATE 2446818-26-2 Acetic acid, 1-methylethyl ester 2446818-27-3 C21 H20 F N3 O3, 381.4 1H-Indole-3-propanamide, 2-(4-fluorophenyl)-N-[(3S,4R)-4-hydroxy-2-oxo-3-pyrrolidinyl]- 3-[2-(4-fluorophenyl)-lH-indol-3-yl]-N-[(3S,4R)-4-hydroxy-2- oxo-pyrrolidin-3-yl ] propanamide use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).   PATENT WO/2021/158666 SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME Compound I is disclosed as Compound 87 …

ONO-2910

It’s only fair to share… ONO-2910 CAS 2410177-35-2 3- [2-[(E) -5- [3- (benzenesulfonamide) phenyl] penta-4-enoxy] phenyl] propanoic acid 3- [2-[(E) -5- [3- (benzenesulfonamido) phenyl] penta-4-enoxy] phenyl] propanoic acid C26 H27 N O5 S 465.56 Benzenepropanoic acid, 2-[[(4E)-5-[3-[(phenylsulfonyl)amino]phenyl]-4-penten-1-yl]oxy]- ONO Pharmaceuticals is developing ONO-2910 , the lead from a program of novel transient receptor potential cation channel 4/5 inhibitors, for treating …

MIRDAMETINIB

It’s only fair to share… MIRDAMETINIB 391210-10-9 Chemical Formula: C16H14F3IN2O4 Molecular Weight: 482.19 PD0325901; PD 0325901; PD-325901; mirdametinib IUPAC/Chemical Name: (R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide SpringWorks Therapeutics (a spin out of Pfizer ) is developing mirdametinib, a second-generation, non-ATP competitive, allosteric MEK1 and MEK2 inhibitor derived from CI-1040, for treating type 1 neurofibromatosis (NF1) and advanced solid tumors. In June …

BELUMOSUDIL

It’s only fair to share… BELUMOSUDIL C26H24N6O2 MW 452.5 911417-87-3, SLx-2119, KD-025, KD 025, WHO 11343 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide 2-(3-(4-(lH-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide Belumosudil mesylate KD025 mesylate 2109704-99-4 Belumosudil mesylate is an orally available rho kinase 2 (ROCK 2) inhibitor being developed at Kadmon. In 2020, the drug candidate was submitted for a new drug application (NDA) in the U.S., under a …

Nanatinostat

It’s only fair to share… Nanatinostat Tractinostat CHR-3996, CHR 3996, VRx 3996, C20H19FN6O2, 394.41 CAS 1256448-47-1 2-[(1α,5α,6α)-6-[[(6-Fluoro-2-q 2-[(1R,5S,6R)-6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide 2-[(1R,5S,6s)-6-{[(6-Fluoro-2-quinolinyl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl]-N-hydroxy-5-pyrimidinecarboxamide 5-Pyrimidinecarboxamide, 2-[(1R,5S)-6-[[(6-fluoro-2-quinolinyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-N-hydroxy- Chroma Therapeutics Ltd. (Originator) OriginatorChroma Therapeutics DeveloperChroma Therapeutics; Viracta Therapeutics ClassAmides; Antineoplastics; Pyrimidines; Quinolines; Small molecules Mechanism of ActionHistone deacetylase inhibitors Orphan Drug StatusYes – Post-transplant lymphoproliferative disorder; Plasmablastic lymphoma; T-cell lymphoma Phase IILymphoma Phase I/IIMultiple myeloma …

TROPIFEXOR

It’s only fair to share… TROPIFEXOR トロピフェクサー; PHASE 2, NASH, PBC, liver fibrosis, bile acid diarrhea, non-alcoholic fatty liver disease Formula C29H25F4N3O5S CAS 1383816-29-2 Mol weight 603.5845 TROPIFEXOR LJN 452;LJN-452;LJN452;CS-2712;CPD1549;Tropifexor;Tropifexor (LJN452);LJN452;LJN452,Tropifexor; 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid тропифексор [Russian] [INN] تروبيفيكسور [Arabic] [INN] 曲匹法索 [Chinese] [INN] 2-[(3-endo)-3-({5-Cyclopropyl-3-[2-(trifluormethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]oct-8-yl]-4-fluor-1,3-benzothiazol-6-carbonsäure [German] [ACD/IUPAC Name] 2-[(3-endo)-3-({5-Cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid [ACD/IUPAC Name] 6-Benzothiazolecarboxylic acid, 2-[(3-endo)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl]methoxy]-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro- [ACD/Index Name] Acide 2-[(3-endo)-3-({5-cyclopropyl-3-[2-(trifluorométhoxy)phényl]-1,2-oxazol-4-yl}méthoxy)-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylique …

TROFINETIDE

It’s only fair to share… Trofinetide Molecular FormulaC13H21N3O6 Average mass315.322 Da Tofinetide , NNZ-2566 10076 853400-76-7 [RN] glycyl-2-methyl-L-prolyl-L-glutamic acid H-Gly-PMe-Glu-OH L-Glutamic acid, glycyl-2-methyl-L-prolyl- UNII-Z2ME8F52QL Z2ME8F52QL трофинетид [Russian] [INN] تروفينيتيد [Arabic] [INN] 曲非奈肽 [Chinese] [INN] IUPAC Condensed H-Gly-aMePro-Glu-OH Sequence GXE HELM PEPTIDE1{G.[*C(=O)[C@@]1(CCCN1*)C |$_R2;;;;;;;;_R1;$|].E}$$$$ IUPAC glycyl-alpha-methyl-L-prolyl-L-glutamic acid An (1-3) IGF-1 analog with neuroprotective activity. OPTICAL ROT; -52.4 °   Conc: 0.19 g/100mL;  water ;  589.3 …

Telacebec

It’s only fair to share… Telacebec Molecular FormulaC29H28ClF3N4O2 Average mass557.006 Da Telacebec, IAP6, CAS No. 1334719-95-7 телацебек [Russian] [INN] تيلاسيبيك [Arabic] [INN] 特雷贝克 10573 1334719-95-7 [RN] 55G92WGH3X 6-Chloro-2-ethyl-N-(4-{4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl}benzyl)imidazo[1,2-a]pyridine-3-carboxamide Imidazo[1,2-a]pyridine-3-carboxamide, 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]phenyl]methyl]- Q203 Q-203 T56 AN DNJ C2 HG BVM1R D- AT6NTJ DR DOXFFF Qurient Therapeutics and Russia licensee Infectex are developing telacebec, an oral formulation which targets QcrB subunit of the cytochrome …